Featured Research

from universities, journals, and other organizations

Evaluation of targeted therapy in ovarian cancer

Date:
October 1, 2010
Source:
Society of Nuclear Medicine
Summary:
New research shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.

Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.

Related Articles


"One of the most promising aspects of molecular imaging is its potential capacity to measure therapy effects long before changes in the tumor size and shape are detected," said Marijke De Saint-Hubert, medical scientist in the Department of Nuclear Medicine at the University Hospital Gasthuisberg, Leuven, Belgium, and one of the authors on an invited perspective article in JNM that comments on the study. It is important to identify response to therapy as early as possible so that ineffective therapies can be discontinued. Patients who are not responding to a given therapy may be suffering from unnecessary side effects and may also be offered potentially more effective treatments.

The chemotherapy drug cisplatin is often effective against ovarian cancer when first given; however, tumors can become resistant to the drug and start growing again, so the need for second-line therapies is pressing. One potential way to overcome cisplatin resistance is to target the mammalian target of rapamycin (mTOR) pathway. The aim of the study was to evaluate the ability of 18F-FLT, a PET probe for cell proliferation, to predict early response to everolimus (an mTOR inhibitor) in a mouse model of subcutaneously transplanted human cisplatin-resistant ovarian cancer.

The study showed that 18F-FLT PET was able to predict early response to mTOR inhibition in a cisplatin-resistant ovarian cancer in mice. The researchers suggest that this technique should be considered for therapeutic assessment in humans. They also point out the technique's potential to non-invasively and longitudinally monitor the efficacy of combination therapy.

"PET imaging could be used to evaluate the treatment's efficacy very early after treatment initiation -- at a time when conventional criteria based on tumor size measurements are useless," said Nicolas Aide, M.D., Centre for Molecular Imaging at the Peter MacCallum Cancer Centre, East Melbourne, Australia, one of the authors of the study.


Story Source:

The above story is based on materials provided by Society of Nuclear Medicine. Note: Materials may be edited for content and length.


Journal References:

  1. N. Aide, K. Kinross, C. Cullinane, P. Roselt, K. Waldeck, O. Neels, D. Dorow, G. McArthur, R. J. Hicks. 18F-FLT PET as a Surrogate Marker of Drug Efficacy During mTOR Inhibition by Everolimus in a Preclinical Cisplatin-Resistant Ovarian Tumor Model. Journal of Nuclear Medicine, 2010; 51 (10): 1559 DOI: 10.2967/jnumed.109.073288
  2. M. De Saint-Hubert, L. Brepoels, F. M. Mottaghy. Can Evaluation of Targeted Therapy in Oncology Be Improved by Means of 18F-FLT? Journal of Nuclear Medicine, 2010; 51 (10): 1499 DOI: 10.2967/jnumed.110.079020

Cite This Page:

Society of Nuclear Medicine. "Evaluation of targeted therapy in ovarian cancer." ScienceDaily. ScienceDaily, 1 October 2010. <www.sciencedaily.com/releases/2010/10/101001163340.htm>.
Society of Nuclear Medicine. (2010, October 1). Evaluation of targeted therapy in ovarian cancer. ScienceDaily. Retrieved March 27, 2015 from www.sciencedaily.com/releases/2010/10/101001163340.htm
Society of Nuclear Medicine. "Evaluation of targeted therapy in ovarian cancer." ScienceDaily. www.sciencedaily.com/releases/2010/10/101001163340.htm (accessed March 27, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 27, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com
What's Different About This Latest Ebola Vaccine

What's Different About This Latest Ebola Vaccine

Newsy (Mar. 26, 2015) — A whole virus Ebola vaccine has been shown to protect monkeys exposed to the virus. Here&apos;s what&apos;s different about this vaccine. Video provided by Newsy
Powered by NewsLook.com
HIV Outbreak Prompts Public Health Emergency In Indiana

HIV Outbreak Prompts Public Health Emergency In Indiana

Newsy (Mar. 26, 2015) — Indiana Gov. Mike Pence says he will bring additional state resources to help stop the epidemic. Video provided by Newsy
Powered by NewsLook.com
Indiana Permits Needle Exchange as HIV Cases Skyrocket

Indiana Permits Needle Exchange as HIV Cases Skyrocket

Reuters - US Online Video (Mar. 26, 2015) — Governor Mike Pence declares the recent HIV outbreak in rural Indiana a "public health emergency" and authorizes a short-term needle-exchange program. Rough Cut (no reporter narration) Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins